Skip to main content
. 2021 Jan 1;12(5):1318–1333. doi: 10.7150/jca.49174

Figure 8.

Figure 8

Forest plot and pooled HR and 95% CI for subgroup OS: “ICI combination therapy” versus “ICI monotherapy”. (a: OS of 1st line; b: OS of “≧2nd line”; c: OS of anti-PD-1 therapy in control group; d: OS of anti-PD-L1 therapy in control group; e: OS of anti-CTLA4 therapy in control group; f: OS of melanoma; g: OS of lung cancer; h: OS of head and neck squamous cell carcinoma) HR, hazard ratios; CI, confidence intervals; OS, progression free survival; ICI, immune checkpoint inhibitor.